Premium
Waiting for Godot: Anticipating answers on embolic protection unlikely to arrive
Author(s) -
Anouti Khalil,
Gray William A.
Publication year - 2018
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.27879
Subject(s) - medicine , asymptomatic , stroke (engine) , embolic stroke , clinical endpoint , surrogate endpoint , intensive care medicine , emergency medicine , surgery , ischemic stroke , randomized controlled trial , mechanical engineering , ischemia , engineering
Key Points For symptomatic and asymptomatic patient with high or intermediate risk of CEA complications, CAS with the use of EPDs has a very low rate of in‐hospital stroke and death There is no statistically significant difference in ipsilateral stroke/TIA and any stroke/TIA between the different device platforms Further efforts to assess differences between EPD devices would likely need to involve a surrogate endpoint due to the very low rates of clinical events